We are happy to report that our research efforts are going well. As many of our shareholders know, ReceptoPharm’s main therapeutic focus is in the neurological (including pain) and antiviral areas.
Recent research highlights include:
Confirming the activity of RPI-78M in animal models of the autoimmune disease Multiple sclerosis, in addition to identifying novel target genes through […]
